Credit Suisse notes that despite the positive trends experienced in 1H22, Cigna maintains a prudent outlook for the rest of the year.
The management noted that, while utilization came in favorable in 2Q22, the company is not extrapolating this to 2H22 and is expecting a more normal utilization pattern, in-line with historical norms.
The company highlighted good performance across the board in the quarter, driven in part by higher Covid contributions and strength from national account partners.
The company expects the extended government Covid contract contribution to be evenly split between quarters for the life of the agreement.
CVS focuses on M&A in primary care, home health, and physician enablement. CVS sees physician enablement as working with providers to enable them to bear risk.
Home care offers considerable opportunity in the digital age and is important in coordinating patient care.
Latest Ratings for CI
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.